$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224002429 Filed on January 16, 2024

Income Statement

Concept	2024 Q1	2023 Q3	2022 Q4
Revenue		$2.058M	$2.529M
YoY Change		-14.26%	5.91%
Cost Of Revenue		$353.5K	$986.4K
YoY Change		-64.6%	-14.06%
Gross Profit		$1.705M	$1.543M
YoY Change		21.58%	24.38%
Gross Profit Margin		82.83%	61.0%
Selling, General & Admin	$5.496M	$2.550M	$1.820M
YoY Change	188.61%	40.95%	-9.99%
% of Gross Profit		149.58%	118.01%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$500.00	$324.4K	$2.820K
YoY Change	-82.28%	1750.43%	34.29%
% of Gross Profit		19.03%	0.18%
Operating Expenses	$5.496M	$2.550M	$1.820M
YoY Change	188.61%	40.95%	-9.99%
Operating Profit	-$5.496M	-$845.1K	-$277.8K
YoY Change	1482.15%	107.64%	-64.49%
Interest Expense	$98.52K	$251.8K	-$183.0K
YoY Change	57.9%	93.52%	8958.91%
% of Operating Profit
Other Income/Expense, Net	-$1.140M	$673.5K	$825.5K
YoY Change	-5356.26%	-653.39%
Pretax Income	-$6.637M	-$171.6K	-$1.303M
YoY Change	1937.68%	-67.54%	66.13%
Income Tax
% Of Pretax Income
Net Earnings	$21.25M	-$3.525M	-$925.2K
YoY Change	-3233.85%	600.81%	17.96%
Net Earnings / Revenue		-171.29%	-36.58%
Basic Earnings Per Share	$20.49	-$4.57
Diluted Earnings Per Share	$16.77	-$1.49	-$0.10
COMMON SHARES
Basic Shares Outstanding	1.205M shares	1.247M shares	9.319M shares
Diluted Shares Outstanding	1.267M shares	2.363M shares

Balance Sheet

Concept	2024 Q1	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.499M	$34.03K	$1.134M
YoY Change	193.01%	-89.42%	-63.7%
Cash & Equivalents	$3.499M	$34.03K	$1.100M
Short-Term Investments
Other Short-Term Assets	$174.2K	$246.1K	$110.9K
YoY Change	-51.31%	-1.48%	-48.74%
Inventory	$5.372K	$3.027M	$119.6K
Prepaid Expenses	$174.2K	$246.1K	$110.9K
Receivables	$6.937K	$850.1K	$729.0K
Other Receivables	$9.041M	$0.00	$0.00
Total Short-Term Assets	$14.03M	$5.548M	$2.093M
YoY Change	487.85%	133.79%	-52.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.000K	$287.9K	$65.21K
YoY Change	-88.78%	323.19%	-33.96%
Goodwill		$5.129M	$0.00
YoY Change
Intangibles	$0.00	$9.452M	$0.00
YoY Change
Long-Term Investments	$2.500M
YoY Change
Other Assets	$22.04K		$49.03K
YoY Change	-55.05%		-18.47%
Total Long-Term Assets	$2.712M	$16.11M	$1.617M
YoY Change	64.23%	595.35%	16.16%
TOTAL ASSETS
Total Short-Term Assets	$14.03M	$5.548M	$2.093M
Total Long-Term Assets	$2.712M	$16.11M	$1.617M
Total Assets	$16.74M	$21.65M	$3.710M
YoY Change	314.57%	361.78%	-35.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$953.1K	$1.329M	$729.2K
YoY Change	84.79%	78.48%	52.85%
Accrued Expenses	$493.4K	$386.0K	$290.0K
YoY Change	62.72%	23.7%	7.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$5.230M	$166.7K
YoY Change		3037.94%
Total Short-Term Liabilities	$2.951M	$9.092M	$2.147M
YoY Change	15.73%	341.08%	131.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$25.00K	$333.3K
YoY Change		-92.5%
Other Long-Term Liabilities	$169.0K	$976.9K	$887.0K
YoY Change	-79.7%	4.14%	-17.1%
Total Long-Term Liabilities	$169.0K	$1.002M	$887.0K
YoY Change	-79.7%	6.81%	-17.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.951M	$9.092M	$2.147M
Total Long-Term Liabilities	$169.0K	$1.002M	$887.0K
Total Liabilities	$3.120M	$10.09M	$3.367M
YoY Change	-7.75%	202.88%	68.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.67M	-$21.53M	-$19.70M
YoY Change	23.97%	14.52%	21.25%
Common Stock	$14.00	$8.00	$99.00
YoY Change	-86.0%	-90.36%	20.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.62M	$11.56M	$763.1K
YoY Change
Total Liabilities & Shareholders Equity	$16.74M	$21.65M	$3.710M
YoY Change	314.57%	361.78%	-35.66%

Cashflow Statement

Concept	2024 Q1	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	$21.25M	-$3.525M	-$925.2K
YoY Change	-3233.85%	600.81%	17.96%
Depreciation, Depletion And Amortization	$500.00	$324.4K	$2.820K
YoY Change	-82.28%	1750.43%	34.29%
Cash From Operating Activities	-$10.19M	-$606.1K	$1.230M
YoY Change	993.86%	5.05%	-388.26%
INVESTING ACTIVITIES
Capital Expenditures	$2.500M	-$140.0K	$115.0K
YoY Change	2771.25%	151.21%	-608.63%
Acquisitions
YoY Change
Other Investing Activities	$29.93M	-$345.7K	$0.00
YoY Change	7022.23%
Cash From Investing Activities	$27.43M	-$205.7K	-$115.0K
YoY Change	8133.14%	269.14%	408.63%
FINANCING ACTIVITIES
Cash Dividend Paid	$12.67M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$13.90M	110.9K	-303.2K
YoY Change	-2139.76%	-1511.32%
NET CHANGE
Cash From Operating Activities	-$10.19M	-606.1K	1.230M
Cash From Investing Activities	$27.43M	-205.7K	-115.0K
Cash From Financing Activities	-$13.90M	110.9K	-303.2K
Net Change In Cash	$3.347M	-700.9K	811.9K
YoY Change	3936.16%	9.42%	-280.7%
FREE CASH FLOW
Cash From Operating Activities	-$10.19M	-$606.1K	$1.230M
Capital Expenditures	$2.500M	-$140.0K	$115.0K
Free Cash Flow	-$12.69M	-$466.1K	$1.115M
YoY Change	1145.79%	-10.58%	-375.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2023Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2023Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest		usd
CY2022Q3	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q3	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash		usd
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	MEDS	Increase Decrease In Inventory Deposits IncreaseDecreaseInInventoryDeposits		usd
	MEDS	Increase Decrease In Inventory Deposits IncreaseDecreaseInInventoryDeposits		usd
	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
	us-gaap	Payments For Software PaymentsForSoftware		usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	MEDS	Proceeds From Payments For Notes Receivable ProceedsFromPaymentsForNotesReceivable		usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MEDS	Note Cancelled From Related Party Agreement Termination NoteCancelledFromRelatedPartyAgreementTermination		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	MEDS	Intangible Asset Contribution From Noncontrolling Interest IntangibleAssetContributionFromNoncontrollingInterest		usd
	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets		usd
	MEDS	Issuance Of Notes Receivable IssuanceOfNotesReceivable		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022Q4	MEDS	Purchase Price Payable PurchasePricePayable		usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue		usd
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39199
	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	261-0281
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	MEDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1205008	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34031	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1094891	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	850103	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	649263	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	3026918	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	68448	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	246093	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	104462	usd
CY2023Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1275000	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	115684	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	176057	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	5547829	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2093121	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	287920	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65214	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9451562	usd
CY2023Q3	us-gaap	Goodwill Goodwill	5129116	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1188385	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051815	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	450845	usd
CY2023Q3	us-gaap	Assets Assets	21653843	usd
CY2022Q4	us-gaap	Assets Assets	3710026	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1328599	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	527984	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	386024	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	271230	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	412390	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67517	usd
CY2023Q3	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	452348	usd
CY2022Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	108036	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	251087	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196872	usd
CY2023Q3	MEDS	Warrant Liability WarrantLiability	1031841	usd
CY2022Q4	MEDS	Warrant Liability WarrantLiability	588533	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	219952	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9092289	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2146791	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	976869	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	887035	usd
CY2023Q3	us-gaap	Liabilities Liabilities	10094158	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3367159	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6666667	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6666667	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	818961	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	818961	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	626247	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	626247	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33089652	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20482666	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21529975	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19719536	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	11559685	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	763136	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-420269	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11559685	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21653843	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3710026	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2058028	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2055803	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5919786	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7993805	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	353450	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	683375	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1072934	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3991234	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1704578	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1372428	usd
	us-gaap	Gross Profit GrossProfit	4846852	usd
	us-gaap	Gross Profit GrossProfit	4002571	usd
CY2023Q3	us-gaap	Salaries And Wages SalariesAndWages	698030	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	849371	usd
	us-gaap	Salaries And Wages SalariesAndWages	2077362	usd
	us-gaap	Salaries And Wages SalariesAndWages	2949386	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	418294	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	82710	usd
	us-gaap	Professional Fees ProfessionalFees	782286	usd
	us-gaap	Professional Fees ProfessionalFees	256807	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	408957	usd
CY2022Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	191007	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	782495	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	567086	usd
CY2023Q3	MEDS	Technology Expense TechnologyExpense	410612	usd
CY2022Q3	MEDS	Technology Expense TechnologyExpense	238577	usd
	MEDS	Technology Expense TechnologyExpense	1010374	usd
	MEDS	Technology Expense TechnologyExpense	690875	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	613834	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	229526	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1264902	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1392130	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2549727	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1591191	usd
	us-gaap	Operating Expenses OperatingExpenses	5917419	usd
	us-gaap	Operating Expenses OperatingExpenses	5856284	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-845149	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-218763	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1070567	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1853713	usd
CY2023Q3	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	925320	usd
	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-443308	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	8396	usd
	us-gaap	Interest Income Other InterestIncomeOther	4198	usd
	us-gaap	Interest Income Other InterestIncomeOther	8396	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	2200	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	251778	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	130107	usd
	us-gaap	Interest Expense InterestExpense	494904	usd
	us-gaap	Interest Expense InterestExpense	140626	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	673542	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121711	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-934014	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-130030	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-171607	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-340474	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2004581	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1983743	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3353507	usd
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-188268	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4123028	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-623096	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3525114	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
	us-gaap	Profit Loss ProfitLoss	-6127609	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3525114	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-503003	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6127609	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2546913	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25739	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-59926	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.22
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.57
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.83
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.52
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.57
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.87
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.51
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-4.35
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.34
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-5.82
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.14
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.42
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.34
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.79
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.14
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.57
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.66
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.64
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	771192	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	549977	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	708116	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	546879	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2363233	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	551724	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2300157	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	548626	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63486	usd
CY2023Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	7	usd
CY2023Q1	MEDS	Stock Issued During Period Value Disposition Of Assets Related Party StockIssuedDuringPeriodValueDispositionOfAssetsRelatedParty	912299	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14434	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-677953	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	655140	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	15813	usd
CY2023Q2	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	1615	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7783	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1974878	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1294527	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3761	usd
CY2023Q3	MEDS	Disposition Of Assets DispositionOfAssets	3875476	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12500089	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3525114	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11559685	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	792500	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	32083	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Distributions NoncontrollingInterestOfCapitalDistributions	-775000	usd
CY2022Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	32783	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-965836	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2887578	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12222	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	16994	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1112261	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63126	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	17661	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1356578	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1356578	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2004581	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1983743	usd
	us-gaap	Depreciation Depreciation	8464	usd
	us-gaap	Depreciation Depreciation	11815	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	25978	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	67439	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	79299	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	107430	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	98841	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4100	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	325916	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29400	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	212292	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-227508	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138450	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-198088	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39013	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19671	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	875250	usd
	MEDS	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	-152121	usd
	MEDS	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	-132847	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-145707	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-120401	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	854171	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	267384	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	43729	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-178714	usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	-5127	usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	105926	usd
	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	443308	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-612184	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2132883	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-593893	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-623096	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1206077	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2755979	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	5546	usd
	us-gaap	Payments For Software PaymentsForSoftware	335902	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	5546	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-312902	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	68737	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	74283	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-312902	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	200000	usd
	MEDS	Proceeds From Payments For Notes Receivable ProceedsFromPaymentsForNotesReceivable	25000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1755688	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	282857	usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	2100000	usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	275000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1622	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	570934	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	268018	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70934	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	268018	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1060860	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2800863	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1094891	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34031	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	321715	usd
	us-gaap	Interest Paid Net InterestPaidNet	494408	usd
	us-gaap	Interest Paid Net InterestPaidNet	3328	usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced	306152	usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
	MEDS	Note Cancelled From Related Party Agreement Termination NoteCancelledFromRelatedPartyAgreementTermination	500000	usd
	us-gaap	Notes Issued1 NotesIssued1	500000	usd
	MEDS	Intangible Asset Contribution From Noncontrolling Interest IntangibleAssetContributionFromNoncontrollingInterest	792500	usd
	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets	492030	usd
	MEDS	Issuance Of Notes Receivable IssuanceOfNotesReceivable	1300000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	115684	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	177536	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.57
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.66
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.64
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.22
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.57
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.83
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.52
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.57
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.87
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.51
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-4.35
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.34
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-5.82
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.14
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.42
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.34
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.79
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.14
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21529975	usd
CY2023Q3	MEDS	Working Capital WorkingCapital	3544460	usd
CY2023Q3	us-gaap	Cash Cash	34031	usd
	MEDS	Gain Loss On Disposal Of Assets GainLossOnDisposalOfAssets	3209776	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	124238	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	344508	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	127671	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	314945	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-3433	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	29563	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	108772	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	87691	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	18079	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	12565	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Accounting And Legal Expense DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense	2648	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Accounting And Legal Expense DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense	604	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	6408	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	60009	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	4391	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	58862	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	140298	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	219731	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-143731	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-190168	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Disposal Of Asset DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset	-3209776	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Disposal Of Asset DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset	1900	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses	-3209776	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses	1900	usd
CY2023Q3	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-3353507	usd
CY2022Q3	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-188268	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-4.35
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.34
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.42
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.34
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	761306	usd
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	925507	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	705206	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1019470	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	56100	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-93963	usd
	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	456297	usd
	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	235758	usd
	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	23371	usd
	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	50534	usd
	MEDS	Disposal Group Including Discontinued Operation Accounting And Legal Expense DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense	70773	usd
	MEDS	Disposal Group Including Discontinued Operation Accounting And Legal Expense DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense	604	usd
	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	30075	usd
	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	151558	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	36592	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	92579	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	617108	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	531033	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-561008	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-624996	usd
	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Disposal Of Asset DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset	-3562020	usd
	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Disposal Of Asset DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset	1900	usd
	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses	-3562020	usd
	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses	1900	usd
	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-4123028	usd
	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-623096	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-5.82
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.14
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.79
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.14
CY2023Q3	MEDS	Annual Base Salary AnnualBaseSalary	400000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2058028	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2055803	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5919786	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7993805	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1895406	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	68448	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1131512	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	3026918	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	68448	usd
CY2023Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	22.50
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding	P4Y7D
CY2023Q3	MEDS	Purchase Price Payable PurchasePricePayable	350000	usd
CY2023Q3	MEDS	Insurance Refunds Payable InsuranceRefundsPayable	62390	usd
CY2022Q4	MEDS	Insurance Refunds Payable InsuranceRefundsPayable	62390	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5127	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	412390	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67517	usd
CY2023Q3	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	452348	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	5230000	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	25000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	5255000	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	24683	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023 the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	0	shares
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumberSplitAdjusted	179331	shares
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	22.50
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P4Y8M19D
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	6731	usd
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedSplitAdjusted	1795	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	22.50
CY2023Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumberSplitAdjusted	177536	shares
CY2023Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	0	usd
CY2023Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumberSplitAdjusted	177536	shares
CY2023Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	22.50
	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P4Y7D
	us-gaap	Share Based Compensation ShareBasedCompensation	25978	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	67439	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80C_eus-gaap--LossContingencyDisclosures_zFS7MPHe6Li5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE 16 – <span id="xdx_82D_zuMWxGuTmZNi">CONTINGENCIES</span></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Studebaker Defense Group, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein IPS would pay Studebaker a down payment of $<span id="xdx_904_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zFBgmDJHwAg3" title="Down payment">550,000</span> and Studebaker would deliver <span id="xdx_90D_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_z4AUzkGOO7Nk" title="Number of nitrile gloves delivered">180,000</span> boxes of nitrile gloves by August 14, 2020. IPS wired the $<span id="xdx_903_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zdWgY9ECVC75" title="Loss contingency damages sought value">550,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion totion vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $<span id="xdx_903_ecustom--LossOnInventoryInvestment_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zEVXjHue8Nmg" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit has been filed to collect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, a settlement was reached in the Studebaker Defense Group LLC. and IPS legal case. The court found in favor of IPS and ordered Studebaker Defense Group, LLC. to pay $<span id="xdx_903_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230412__20230413_z9msQ6H862Q7" title="Repayments of related party debt">550,000</span> IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 installments until the full amount is paid in full but as of the filing date, no payment has been received by IPS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, IPS entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein IPS would pay Sandwave a down payment of $<span id="xdx_90C_ecustom--DownPayment_c20200801__20200831__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zh8gjUwbdZLl" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_90A_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IPSMember_zYV9tzPcZauf" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. IPS wired the $<span id="xdx_90B_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IPSMember_zt53rm7WBbk7" title="Loss contingency damages sought value">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. IPS demanded return of its $<span id="xdx_90A_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember__dei--LegalEntityAxis__custom--IPSMember_zheGCRxIgLe6" title="Loss contingency damages sought value">581,250</span> and Crecom acknowledged that IPS was entitled to a refund. As of February 2021, Crecom had not returned any funds and IPS filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by IPS was stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for IPS. At June 30, 2021, the $<span id="xdx_903_ecustom--LossOnInventoryInvestment_c20210101__20210630__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zYGBpupHNthe" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GSG PPE, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930_zWvjJawUBJuk" title="Principal amount">630,000</span> which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_90F_ecustom--AttorneyFees_c20230101__20230930_zqL5uLhcWzJf" title="Attorney fees">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed IPS $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__srt--TitleOfIndividualAxis__custom--WaxmanMember_zcOHlIMwXOg6" title="Principal amount">630,000</span>. On September 30, 2021, the $<span id="xdx_900_eus-gaap--ProvisionForDoubtfulAccounts_c20210928__20210930_zOQlc75wNrw5" title="Bad debt expenses">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_905_eus-gaap--LegalFees_c20220601__20220630_zJdkUj0kjxi3" title="Attorney fees">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received additional monthly installment payments as part of the agreement through January 2023. As of September 30, 2023, and through the date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	550000	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
	MEDS	Attorney Fees AttorneyFees	630000	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	630000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	743000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5919786	usd
	us-gaap	Gross Profit GrossProfit	4846852	usd
CY2023Q3	us-gaap	Assets Assets	21653843	usd
	us-gaap	Profit Loss ProfitLoss	-6127609	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1072934	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7993805	usd
	us-gaap	Gross Profit GrossProfit	4002571	usd
CY2022Q3	us-gaap	Assets Assets	4480317	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3991234	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
meds-20230930_cal.xml	Edgar Link	unprocessable
meds-20230930_lab.xml	Edgar Link	unprocessable
0001493152-24-002429-index-headers.html	Edgar Link	pending
0001493152-24-002429-index.html	Edgar Link	pending
0001493152-24-002429.txt	Edgar Link	pending
0001493152-24-002429-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
form10q_003.jpg	Edgar Link	pending
meds-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
meds-20230930_def.xml	Edgar Link	unprocessable
meds-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2024 Q1 Form 10-Q Financial Statement

#000149315224002429 Filed on January 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2024 Q1 Form 10-Q Financial Statement

#000149315224002429 Filed on January 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx